C-type natriuretic peptide co-ordinates cardiac structure and function.
Heart failure
Cardiomyocyte
Endothelium
Ischaemia/reperfusion injury
Natriuretic peptide
Natriuretic peptide receptor
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
received:
28
09
2018
revised:
21
12
2018
accepted:
26
02
2019
pubmed:
25
3
2019
medline:
15
5
2021
entrez:
24
3
2019
Statut:
ppublish
Résumé
C-type natriuretic peptide (CNP) is an essential endothelium-derived signalling species that governs vascular homoeostasis; CNP is also expressed in the heart but an intrinsic role for the peptide in cardiac function is not established. Herein, we employ unique transgenic strains with cell-specific deletion of CNP to define a central (patho)physiological capacity of CNP in maintaining heart morphology and contractility. Cardiac structure and function were explored in wild type (WT), cardiomyocyte (cmCNP-/-), endothelium (ecCNP-/-), and fibroblast (fbCNP-/-)-specific CNP knockout mice, and global natriuretic peptide receptor (NPR)-B-/-, and NPR-C-/- animals at baseline and in experimental models of myocardial infarction and heart failure (HF). Endothelium-specific deletion of CNP resulted in impaired coronary responsiveness to endothelium-dependent- and flow-mediated-dilatation; changes mirrored in NPR-C-/- mice. Ex vivo, global ischaemia resulted in larger infarcts and diminished functional recovery in cmCNP-/- and NPR-C-/-, but not ecCNP-/-, vs. WT. The cardiac phenotype of cmCNP-/-, fbCNP-/-, and NPR-C-/- (but not ecCNP-/- or NPR-B-/-) mice was more severe in pressure overload- and sympathetic hyperactivation-induced HF compared with WT; these adverse effects were rescued by pharmacological CNP administration in WT, but not NPR-C-/-, mice. At a molecular level, CNP/NPR-C signalling is impaired in human HF but attenuates activation of well-validated pro-hypertrophic and pro-fibrotic pathways. C-type natriuretic peptide of cardiomyocyte, endothelial and fibroblast origins co-ordinates and preserves cardiac structure, function, and coronary vasoreactivity via activation of NPR-C. Targeting NPR-C may prove an innovative approach to treating HF and ischaemic cardiovascular disorders.
Identifiants
pubmed: 30903134
pii: 5418562
doi: 10.1093/eurheartj/ehz093
pmc: PMC7068173
doi:
Substances chimiques
Natriuretic Peptide, C-Type
127869-51-6
Atrial Natriuretic Factor
85637-73-6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1006-1020Subventions
Organisme : British Heart Foundation
ID : PG/18/75/34096
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/13/58/30648
Pays : United Kingdom
Organisme : Worldwide Cancer Research
ID : 12-1068
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 12007
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/7/32357
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
J Am Coll Cardiol. 2005 Feb 15;45(4):608-16
pubmed: 15708711
Am J Cardiol. 2008 Sep 8;102(5A):21G-28G
pubmed: 18722188
Heart Fail Rev. 2007 Dec;12(3-4):279-91
pubmed: 17516166
Br J Pharmacol. 1999 Sep;128(1):206-12
pubmed: 10498853
J Biol Chem. 1995 Mar 3;270(9):4668-74
pubmed: 7876238
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4735-40
pubmed: 16537417
Peptides. 2011 Aug;32(8):1713-8
pubmed: 21723350
J Physiol. 2015 Mar 1;593(5):1127-46
pubmed: 25641115
Circulation. 2004 Sep 7;110(10):1231-5
pubmed: 15337698
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17300-5
pubmed: 15572448
J Mol Cell Cardiol. 2012 Nov;53(5):715-24
pubmed: 22960454
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
Circulation. 1993 Sep;88(3):1004-9
pubmed: 8353861
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1426-31
pubmed: 12552127
Endocrinology. 2004 May;145(5):2129-30
pubmed: 15087437
Circulation. 2003 Mar 11;107(9):1278-83
pubmed: 12628948
Hypertension. 2017 Feb;69(2):286-296
pubmed: 28049696
Peptides. 2008 Dec;29(12):2208-15
pubmed: 18848850
FEBS Lett. 1995 Oct 9;373(2):108-10
pubmed: 7589445
J Clin Invest. 2005 Jun;115(6):1666-74
pubmed: 15931395
Exp Biol Med (Maywood). 2004 Sep;229(8):813-8
pubmed: 15337836
Circulation. 2018 Jul 31;138(5):494-508
pubmed: 29626067
Biochem J. 1993 Apr 1;291 ( Pt 1):83-8
pubmed: 8097089
J Clin Invest. 2014 Sep;124(9):4039-51
pubmed: 25105365
Hypertension. 2009 Sep;54(3):612-8
pubmed: 19620509
Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7428-E7437
pubmed: 30012589
Int J Cardiol. 2014 Jul 1;174(3):e84-6
pubmed: 24809913
PLoS One. 2012;7(12):e52422
pubmed: 23272242
Am J Physiol. 1998 Oct;275(4):L645-52
pubmed: 9755096
Eur J Heart Fail. 2007 Jun-Jul;9(6-7):548-57
pubmed: 17407830
Basic Res Cardiol. 2010 Sep;105(5):583-95
pubmed: 20352235
Cardiovasc Res. 2019 Feb 1;115(2):357-372
pubmed: 30239604
Cardiovasc Res. 2016 Dec;112(3):637-644
pubmed: 27496871
Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7403-8
pubmed: 10377427
Am J Physiol. 1999 Dec;277(6):H2280-9
pubmed: 10600847
Endocrinology. 1993 Apr;132(4):1872-4
pubmed: 8462485
J Cardiovasc Med (Hagerstown). 2006 Jun;7(6):397-9
pubmed: 16721200
Eur J Heart Fail. 2005 Dec;7(7):1145-8
pubmed: 15922659
Endocrinology. 2007 Jul;148(7):3518-22
pubmed: 17412809
Proc Natl Acad Sci U S A. 2002 May 14;99(10):7142-7
pubmed: 11997476
Am J Physiol Heart Circ Physiol. 2004 May;286(5):H1970-7
pubmed: 14704228
Science. 1991 Apr 5;252(5002):120-3
pubmed: 1672777
J Clin Invest. 2003 May;111(9):1399-407
pubmed: 12727932
Endocrinology. 2003 Jun;144(6):2279-84
pubmed: 12746286
PLoS One. 2014 Jan 22;9(1):e85708
pubmed: 24465655
Circ Res. 2018 Mar 2;122(5):742-751
pubmed: 29326144